These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 22466336)

  • 1. Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis.
    Murad MH; Drake MT; Mullan RJ; Mauck KF; Stuart LM; Lane MA; Abu Elnour NO; Erwin PJ; Hazem A; Puhan MA; Li T; Montori VM
    J Clin Endocrinol Metab; 2012 Jun; 97(6):1871-80. PubMed ID: 22466336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis.
    Barrionuevo P; Kapoor E; Asi N; Alahdab F; Mohammed K; Benkhadra K; Almasri J; Farah W; Sarigianni M; Muthusamy K; Al Nofal A; Haydour Q; Wang Z; Murad MH
    J Clin Endocrinol Metab; 2019 May; 104(5):1623-1630. PubMed ID: 30907957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
    Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
    Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Summary of AHRQ's comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report.
    Levis S; Theodore G
    J Manag Care Pharm; 2012 May; 18(4 Suppl B):S1-15; discussion S13. PubMed ID: 22716221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis.
    MacLean C; Newberry S; Maglione M; McMahon M; Ranganath V; Suttorp M; Mojica W; Timmer M; Alexander A; McNamara M; Desai SB; Zhou A; Chen S; Carter J; Tringale C; Valentine D; Johnsen B; Grossman J
    Ann Intern Med; 2008 Feb; 148(3):197-213. PubMed ID: 18087050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How to manage postmenopausal osteoporosis?
    Body JJ
    Acta Clin Belg; 2011; 66(6):443-7. PubMed ID: 22338309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis.
    Moshi MR; Nicolopoulos K; Stringer D; Ma N; Jenal M; Vreugdenburg T
    Calcif Tissue Int; 2023 Jun; 112(6):631-646. PubMed ID: 37016189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis.
    Reginster JY
    Drugs; 2011 Jan; 71(1):65-78. PubMed ID: 21175240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.
    Ayers C; Kansagara D; Lazur B; Fu R; Kwon A; Harrod C
    Ann Intern Med; 2023 Feb; 176(2):182-195. PubMed ID: 36592455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of osteoporosis treatment on mortality: a meta-analysis.
    Bolland MJ; Grey AB; Gamble GD; Reid IR
    J Clin Endocrinol Metab; 2010 Mar; 95(3):1174-81. PubMed ID: 20080842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review.
    Crandall CJ; Newberry SJ; Diamant A; Lim YW; Gellad WF; Booth MJ; Motala A; Shekelle PG
    Ann Intern Med; 2014 Nov; 161(10):711-23. PubMed ID: 25199883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: A systematic review and network meta-analysis.
    Simpson EL; Martyn-St James M; Hamilton J; Wong R; Gittoes N; Selby P; Davis S
    Bone; 2020 Jan; 130():115081. PubMed ID: 31626995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.
    Cheng LI; Durden E; Limone B; Radbill L; Juneau PL; Spangler L; Mirza FM; Stolshek BS
    J Manag Care Spec Pharm; 2015 Sep; 21(9):824-33, 833a. PubMed ID: 26308229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of postmenopausal osteoporosis and the prevention of fractures.
    Gambacciani M; Levancini M
    Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
    Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
    Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis.
    Nicolopoulos K; Moshi MR; Stringer D; Ma N; Jenal M; Vreugdenburg T
    Arch Osteoporos; 2023 Jan; 18(1):18. PubMed ID: 36624318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indirect comparison of teriparatide, denosumab, and oral bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis.
    Zhang L; Pang Y; Shi Y; Xu M; Xu X; Zhang J; Ji L; Zhao D
    Menopause; 2015 Sep; 22(9):1021-5. PubMed ID: 25944523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developments in the pharmacotherapeutic management of osteoporosis.
    Close P; Neuprez A; Reginster JY
    Expert Opin Pharmacother; 2006 Aug; 7(12):1603-15. PubMed ID: 16872263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ranking antireabsorptive agents to prevent vertebral fractures in postmenopausal osteoporosis by mixed treatment comparison meta-analysis.
    Migliore A; Broccoli S; Massafra U; Cassol M; Frediani B
    Eur Rev Med Pharmacol Sci; 2013 Mar; 17(5):658-67. PubMed ID: 23543450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy and safety of pharmacological interventions for osteoporosis in postmenopausal women: a network meta-analysis (Chongqing, China).
    Tan X; Wen F; Yang W; Xie JY; Ding LL; Mo YX
    Menopause; 2019 Aug; 26(8):929-939. PubMed ID: 31021904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.